Koyi Med develops a portfolio of cannabis-derived pharmaceutical raw materials in Poland. We work with an Australian partner in the medical sector, focusing on quality control, batch traceability and a responsible supply chain.
Information about individual raw materials and their specifications is intended for authorised professionals.
Confirm the declaration to reveal this part of the website.
Koyi Med is responsible for portfolio development and regulatory documentation. We work with partners involved in import and distribution and support professional customers with information about our raw materials.
Explore the greenhouse growing environment in Australia.
01 / 04 · Greenhouse cultivation
Four stages — from cultivation to batch release. Expand a stage to explore what it involves.
Documentation connects each stage of the process. Test results and specifications relate to a specific batch of raw material.
Documented origin and controlled greenhouse growing conditions.
Documented origin and controlled greenhouse growing conditions.
Natural light and controlled growing conditions in Victoria.
Processes follow applicable quality requirements, with oversight of packaging integrity.
Packaging illustration
Packaging and the protective closure form part of the system that safeguards the raw material.
Batch specifications are assessed using relevant tests, certificates of analysis and product documentation.
Results relate to a specific batch. Assessment is based on certificates of analysis (CoA) and product documentation.
Activities required within the regulated pharmaceutical supply chain are carried out with authorised partners.
Documentation and the involvement of authorised partners support traceability throughout the supply chain.
Detailed chemical profiles and technical information are available in the professional area.
Confirm the declaration to reveal this part of the website.
Australia.
A view of cultivation.
Composition, terpene profiles and packaging information for physicians, pharmacists and authorised pharmaceutical operators.
We welcome enquiries from healthcare professionals and pharmaceutical partners about cooperation, availability and documentation.
Contact our team ↗Information about Koyi Med pharmaceutical raw materials
This section contains detailed technical information about cannabis-derived pharmaceutical raw materials. It is intended exclusively for professionals authorised to prescribe or trade in medicinal products. Product information relates to the Polish market and does not establish authorisation or availability in another country.
This declaration applies to the current page view. Privacy information
Select the declaration to access product information.
Cannabis flos THC 19%, CBD ≤1%, Koyi Med
Polish authorisation no. 30178
Royal Moby is a sativa-dominant cultivar (65%) with a terpene profile led by terpinolene. Terpene composition may vary between production batches.
*Indicative terpene profile. Values may vary between batches and do not replace the certificate of analysis (CoA).
Royal Moby — cannabis flower photograph.
Aroma profile: citrus, herbal and spicy notes with berry accents. The aroma description refers to the cultivar’s botanical characteristics.
Quality specifications for an individual batch must be established using its certificate of analysis (CoA) and applicable documentation.
Green Gelato is a cannabis cultivar with a distinctive terpene profile dominated by β-myrcene, with significant contributions from α-pinene and β-pinene. This profile is indicative; composition may vary between batches.
Other terpenes: approx. 30%. Percentages describe relative proportions within the terpene profile, not the total dry flower weight.
Contact us for current specifications, a batch-specific certificate of analysis or availability. Please identify the raw material and, if known, the batch number.
Request documentation ↗